Advances in therapy for spinal muscular atrophy: promises and challenges

EJN Groen, K Talbot, TH Gillingwater - Nature Reviews Neurology, 2018 - nature.com
Nature Reviews Neurology, 2018nature.com
Spinal muscular atrophy (SMA) is a devastating motor neuron disease that predominantly
affects children and represents the most common cause of hereditary infant mortality. The
condition results from deleterious variants in SMN1, which lead to depletion of the survival
motor neuron protein (SMN). Now, 20 years after the discovery of this genetic defect, a major
milestone in SMA and motor neuron disease research has been reached with the approval
of the first disease-modifying therapy for SMA by US and European authorities—the …
Abstract
Spinal muscular atrophy (SMA) is a devastating motor neuron disease that predominantly affects children and represents the most common cause of hereditary infant mortality. The condition results from deleterious variants in SMN1, which lead to depletion of the survival motor neuron protein (SMN). Now, 20 years after the discovery of this genetic defect, a major milestone in SMA and motor neuron disease research has been reached with the approval of the first disease-modifying therapy for SMA by US and European authorities — the antisense oligonucleotide nusinersen. At the same time, promising data from early-stage clinical trials of SMN1 gene therapy have indicated that additional therapeutic options are likely to emerge for patients with SMA in the near future. However, the approval of nusinersen has generated a number of immediate and substantial medical, ethical and financial implications that have the potential to resonate beyond the specific treatment of SMA. Here, we provide an overview of the rapidly evolving therapeutic landscape for SMA, highlighting current achievements and future opportunities. We also discuss how these developments are providing important lessons for the emerging second generation of combinatorial ('SMN-plus') therapies that are likely to be required to generate robust treatments that are effective across a patient's lifespan.
nature.com